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O&ctiws. This study sought to develop and valiite a Jtayes- 
ian risk predictioo model for vascular surgery candidater 
/lfzcm. Patients who reqoire surgical treatment of peripb- 
era1 vascular disease are at increased risk of perioperative cardiac 
morbidity and mortality. Extsting prediio models tend to 
underestimate risk in vascular sorgery candidates. 
Mepkods. The cohort comprised l,@Sl consecutive vascular 
smpry cadiites at five medical centers. Of tbcse, 567 patients 
from two ceote~ (9rt&dngw set) we. L ased to dt. . lop the mo* 
aod 514 patients from three tea,. .b wwv us& In validate it 
(“validation” set). Risk scores we- develow lsing logistic 
regression for clinical variablesz advanced age i>?tl years), an- 
pi& history of myoranlial infarct&r. jiabetes mellitns, bistwy of 
congestive heart faihue and prior coromuy revasculartzatioa. A 
second model was develop4 f&n dipyridamol&hallium predic- 
tors of myocardial infarction (i.e., fixed and reversible myocardial 
defcctsandSTcbangca).Mode4pclco- wa6ameamdby 
comparingobservedevent~~withriskestimatesandbype-rfob 
irlg Kceh-omtlog chalwaistic cmve (WC) analy&. 
Patients who require surgical treatmeut of peripheral vascular 
disease are a! increased risk of perioperative cardiac morbidity 
and mortr’lty reiated booth to the surgical procedure and to 
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ltemkr. The postoperative cardiac event rate was 89c for both 
sets. Pmgnostic accuracy (i.el WC area) wcs 71 + 3% (mean f 
SD) for the clinical and 81 2 3% for the clinical and 
dipyrklamole-thalliu models. Among the validation sets, areas 
were 74 f 9%, 72 2 7% aad 76 + 5% for each center. Observed 
and estimated rates were comparable for both seta. By the elinii 
modei, tbc observed rates were 34b, 8% and IS% for patients 
chaifled as low, moderate and bii risk by diil factors (p c 
Q.Wl). The addition of dipyrhkmml&hall+n data rectassiticd 
>SQ% of the moderate risk patients into low (3%) aod hii (19%) 
iiskca@ories(p<0.@001)butprovidednostxati6caWfor 
paticntsdassiiasloworkighEskaccord&tothcdinicalmodet. 
Ciu&&is. Simple ciinical marBers, weighted accorxiii to 
prognostic impact, will reliably stratify risk in vascaku sorgery 
candidates referred for diiridamde-thalliu testin& thus sbvi- 
sting the need for the more expensive testing. Oar pAdiain 
model retains its progmstic accuracy when applied to the valida- 
tioa sets and can reliably estimate risk in this group. 
(J Am Cd Cordid 1996;27:7’19-86) 
-- 
concomitant coronary atherosclerosis (l-10). To reduce the 
incidence of perioperative cardiac events among vascular 
surgery candidates, clinicians have sought methods to stratify 
cardiac risk in individual patients. Patient management may 
thus be influenced by the patient’s risk classification. For 
example, surgical treatment may be= deferred or ntodified to a 
less invasive therapy in high risk patients. Others, deemed to 
be at moderate risk of early events, may be further classified 
into more sperific risk categories by conducting diagnostic tests 
for the detection of coronary disease. Finally. low risk patients 
tight avoid further testing and undergo operation directly,, 
thus reducing cost, test-related morbidity and possible unnec- 
essa? coronary angiography. 
According to D&sky et al. (11.12) and Eagle and Boucher 
(13), the first step in the assessment of risk is to consider the 
average risk of a major perioperative cardiac event amcng 
vascular surgery candidates. Factors such as referral patterns, 
general patient characteristics, surgical expertise and patient 
management will determine this level of risk for a particular 
mcdtcal institution. This v,duc, referred IO a% Ihc r\,mplication 
rate or. In Bayesian tctmc, rhc p&r p&&;.,~ may bc 
regarded as unique to a given mbtitution and a+ $uch rhould be 
supplied hy the clmrlan who w&s to compute a pam~Iti ;rrk 
esIima~r. Subuzqucmly. usin a &lye&an apptoach (t4), chtu- 
clans should then petfotm “ta&” for each patient, which 
inch& gathering clinical daIa and conducting noninvasive 
stteu testing. The goal of these test5 is to tevise the prior 
ptobabiliry to a pnmcsr pobobifity that is mote representative 
of the patient’s characteristics. To he practical, Ibese revised 
risk esIimaIes should be easily obtainable by the clinician “in 
the field.” 
Although Bay&n mod& of cardiac risk asscsment (e.g., 
the Modified Clinical Risk Index of DeIsky CI al. [Ill) have 
been devekvd for general surgical p@aItons, such models 
tend IO undete+IimaIe risk in varculat surgery ctindidater 
because of their higher prevalence of underlying coronary 
disease. In tespoose IO these concerns, Eagle ci al. (15) 
developed a non-Bayesian ptcdiflot algorithm from a co- 
hort of va~ulrt sutgety candidaIc< !haI incorporates a series of 
clinical risk factors and the results of a pharmacologic 
stress Iesl using dipytidamole-thallium scintigtaphy (16). 
DipyTidam-ole-thallium scinrigraphy is a sensi~ne predictor of 
major petiopetative cardiac motbiiiIy (17-23). However, the 
initial citetia used were based simply on the number of 
predicton pte.wn~+ In the catly model (15). each factor’s 
quunGIative ctnlrihuIion IO tIsk (i.e., weight) was not comid- 
wed. Although this approach was lalet mrx:ified to incorporate 
Ihe weighted value of each ptedicot (24). the actual risk 
compuIaGon proved cumbersome. In addition, Ihe outcome of 
interest was defined as a ;?tdiac irhemic event (mcludmg 
unstable angina) tathct than the ..hard” end poinIs of nonfatal 
myocatdial infarction or cardiac dcarh, 
Accordingly, we sough1 IO develop a simplified Bay&n 
method for the assessment of the risk of postoperative myo- 
catdial infatcIion or cardiac dearh in vascular surgery candi- 
daIc+, No compuktlion othct than Gmplc ;IddlIion 15 requited. 
The climcum can rcaddy obtain a pcritrptativc risk csIimaIc 
Iha! incorporalc$ the palien\‘, clinical or tc’rI sIaIu~. 01 h+Ih. 
with It-f: prior p&ah&y of ;I \crIous cdtdiac cvcnI. 
hlethods 
Training se& The model WAS developed from a “Inining” 
set of 1%6 consecutive varulat surgery cand;d;ltc\ referred IO 
the cardiac nuclrat labota~trry rot ~i~tidamc~lc-Ihallior~~ Ie\I. 
inp i&trc major clcclivc rarulat 5utgery :II Iwo univcrsiry 
ho\prtal\ (246 from MdswchuscIIs Gencrdl Hospiral, Boston. 
and 3&l from Ihe UniveniIy of Massachuutts Medical Ccntcr, 
Worceh~ct) between Augu\t I984 and Deccmbct l(J9l. a’r 
prevtously described (1’!.24). ThItty nine paGents wctc cx- 
cl&d txre~rc ~;lscular qyry wtis p(qxmL1 or canceled 
h&%uu: of wVellly Of coronirty diWilW. The rcmrioing 567 
psiienls who received prompr vascular \utgcty comprised the 
cohort. 
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Vnll&tkm set. The validutmn set irticluded an addiGonal 
531 paIicnIs fn,m Ihtce univcnily medical centets: I67 fmm 
Deuconcss tiospilal. Boston. 17s putienIs from Medical Cen- 
Ier Hospital of Vetmonl. Burlington, and 172 patients from 
Yale Unirctsily, New Haven. (‘onristent with the training set. 
all subjcc?r wcte conscct+Iivc elective vitsculat sutgcty candi- 
da& tcfettcd to their insIitulion’s respective nuclear catdiol- 
ogy laboratories Lt dipytidamole-thallium testing from Janu- 
aty 1988 IO September 1991. A total of 33 patients were 
excluded because vascular surgery was postponed or canceled 
for severity of coronary disease. 
The Iota1 study cohort is therefore 1,081 patients, 
IUsk factor se&&m. Variables identified as independent 
ptcdicton of major petiopetaIive cardiac events (,i.c., nonfatal 
myocatdial infarction or cardiac death) by consensus of the 
study investigators and supported by data from published 
teprrs (17-28) were selected for inclusion inlo the logistic 
models. These wctc Ihe presence of the following: advanced 
age (>7U years), history of angina, history of myocatdisl 
infarction or eleatocatdiogIrphic (ECC) 0 waves, history of 
diaberes mellitus and hisIoty of congestive heart failure. Ad- 
ditionally, coronary revasculatization that occurred 1 month to 
5 years (mean 2.4 t 0.8 ye.us) before the current hospital 
peti& and was shown to bc p;otectivc for postoperative 
myocatdial infarction in the cutten cohort and elsewhere 
(2930). For the training set, clinical and histotical information 
was obtained tettospedively from the medii record by 
investigaton who reviewed records up to, but not including, 
the operalive chart. For the validation sets, clinical and hiitor- 
ical information was obtained prospectively, that is, before 
operation. Clinically teltvant dipytidamole-thallium results 
were described ar I) ischemic ECG changes. defined as a 
z I mm S’T scgmenl dcptession compared with baseline levels; 
I) planar myocatdial rintigtaphic images that on review by 
Iwo experienced observers showed fixed defects: and 3) images 
showing defecls that partially or completely redititributed on 
delayed (>3 h) imaging, 
Outcomr detemtinet!oa. At all ccntets, oulcomes were 
aswcsed by rr:dical record review and or intetview of th? 
treating physicians, the patients and their families. Outcomes 
of interest were nonfatal or fatal myocardial infarction or 
cardiac death. All patients were monitored by daily ECGs and 
serum cardiac enzyme levels (creatinine kinass-MB fraction 
[CK-hlB]) for 72 h after opetarion For the definition of 
myocardial infarction, Ihc University of Minnesota criteria 
were uwd: new lX’(i 0 wave h I mm or C’K-MB rl;%’ or both. 
F;lIal cardiac events were defined as sudden death dire&y 
altrihutahle to myoccardial infarction, congestive failure or 
ventricular arrhythmia. All reported faatal events were con- 
firmed by tcGew of ho#al records. autopsy (inding and 
dc;tIh cettiticatcs. All tcporlcd non&al evenI,+ wc:tc’ confirmed 
by medical tecurd rev& lot Ihe flC’G or snrymc ctiletia, or 
both. cilcd ptcviously. 
Model devrlopmcnt. Two spccitied logistic regression mod- 
els were developed using BMDP LR (BMDP Qatistical soft- 
ware. Inc.) !&ware: clinical and dipytidamole-thallium vati- 
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21 (db’k ) 
32 (70%) 
24 (52%) 
?I(‘wJ%) 
I7 (37%) 
II) (229 ) 
I (2%) 
l?h(W%J I,6 (o.lr~-3.0, 
,348 (67%) I.1 (0.6-2.2) 
I% (37%) 1.8(l.l-3.3) 
127(24%) 2.c (l.d-d.8) 
I05 (20%) 2.3 (1.3-4.4) 
4V (or;r ) 2.7 (I .3-.5.?) 
h7(13’%) 0.2 (I). I-0 9) 
1.2 (0.6-2.4) 0.517 
0.7 (lkd-1.4) u.w 
d.1(2.C-ILO) aalo 
I.1 (0.5-2 3) 0.755 
Z.O(I O-4.1) uoda 
.l,Z(l 64AJ lmlt 
I2(tlr 31) IJMJ 
I n (0.Y .3,4) lltt76 
26(1 J-5.2) lla33 
2.70 ?-6.11 0.01 t 
abies were regressed separately bccausc it was anticipated that 
in practice the models would be applied II) patient? who had 
not yet undergone dipyridamole-thallium testing and for 
whom these variables would be undefined. Appropriate inter- 
action terms were also considered among the clinical variables, 
such as the possible interaction between advanced age and any 
of the cardiac or diabetic variables. 
A Elayesian framework for the analysis permits the clinician 
to consider both the average risk (prior probability) and the 
patknt-specific predictive diagnostic information, which is 
referred to as the likelihood ratio (31). A likelihcmd ratio is 
typically computed for each clinical variable or test result from 
the proportion of patients with a particular result who cxpcri- 
ence an event divided by :he proportion who do not expericncc 
the event. Likelihood ratios >I yield a patient risk ertimatc 
greater than the average risk. Conversely. likelihtxti ratios iI 
imply that the patient’s risk is below the average. One of the 
advantages to the use of likelihood ratios is that risk estimates 
can be revised sequentially, first by the likelihood ratios 
obtained for the set of clinical factors alone, then by the 
dipyridamole-thallium results if necessary. In this study, like- 
lihood ratios were derived from logistic regression analyses 
using a previously described method (??-37). 
Model vaNdalion. Ultimately, any predictive model should 
be validated by comparing risk estimates to observed event 
Iates in both the challenge and validation sets Validation 
procedures arc typically rlesigncd to assc~ discrimination (3H) 
and calibration (39) pcrformancc. c’olihru~ion rcfcrs to compa 
rability hL,,rccn obsctvcd and estimated rates. Di.wMmrion 
dePcribca u model’r ability IO separate a population into those 
who will experience the event and those who will not. Typically, 
“goodness of 61” tests (39) and receiver-operating charactcr- 
istic (ROC) curies (38) are used to evaluate a mod& 
calibration and discrimination, respectively. 
Re!3ulta 
Dlstrlbution of rlalt factora tacoding to outcome, The 
distributions of clinical and dipyrid~mole-thallium variables 
according to outcome is shown in Table I for perioperative 
events (all patients). There were 46 events (30 nonfatal, 16 
fatal) among the 567 training set patient% (g%) and 39 events 
(27 nonfatal, I2 fatal) among 514 validation set patients (6%). 
With the exception of gender and perhaps advanced age, all 
clinical and all dipyridamole-thallium vuriabks in the training 
set were more prevalent among those patients with than 
without an event. l’hc computed udds ratios alss indicate a 
significant association between clinical and dipyridamolc- 
thallium variablca and autcomc. Thcrc ii i also evidence of a 
protective effect among patients who underwent a priur corn 
nary bypa% proccdurc within 5 years. Three of the six clinical 
variables (prior myocardial infarction, diabetes, congestive 
heart failure) in the validation set were associated with events, 
and all dipyridamole-thallium variables were associated with 
outcome. 
The major cardiac complication rates (nonfatal myocardial 
infarction, cardiac death) c!a&tcd according to type of vm 
lar surgical procedure arc shown in Table 2 for both the 
training and validation sets, These values thus correspond, to 
the procedure-specific prior probability of a cardiac event. 
Event rates in the training set were signifkzantly greater for 
infrainguinal(l3%, 95% cc,nfidencc interval [Cl] 8% to 18%) 
than for aortic (69,9S% Cl 4% IO 8%) or carotid @b/r, 95% 
Cf I% to HI%,) procedures (p = 0.012). Again, event rates in 
the validation set were gredter for infrainguinal (ION 95% Cl 
72 to 145 ) than aortic (6%. 95% Cl 2% to IZ%,) or carotid 
(6%. 9SCi. CI 3’% to 12%) prccedures, although these differ- 
ences were not statistically significant. 
The logistic regrcssioc!ana&scs are detailed in Table 3. 
Among the model I clinical variables, a history of diabetes, 
angina, and prior ooronary revascularization remained strongly 
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as~s~ated with otncomc Ntr intcraclion trrrn> wrrc found to 
contrib& IO the model A!I rar~ihlc~ in thr dipyrtdamolc- 
thalhum m&l (model 2) arc stgnific mtty predrtivc of out- 
Lvrne. 
Vslidatiua results. The ROC curves for the clinical and 
sequentially applied (climcal plus dipyridamole-thallium) 
mtxlrls devclopcd from the tratrling set are shown in Figure 1, 
Progntntic iwcuracy. a\ cxpresscd by the ROC areas, was 74 t 
3% for the clinica: m&l and XI + 3% for the sequentially 
applied models. 
Figure 2 displays the comparative prognostic ;tLruraq of 
the training and indivdual validation set patients for the 
wquentially applied model recording to ROC areas. Areas 
were RI 1 Yi for the training VI, and 74 t 9%. 72 + 7% and 
7h t 5% for each al the three rrnters reprcwnting the 
validation set. 
Calibration results are displayed graphically in Figure 3 for 
both the training and validation XI\ at four risk categories. 
Values for the tfc~mcr~lrmc~htnv grxdne\\ of fit stal,sric, f‘ 
(39). computed from the observed and cstimaiod c\~t frc- 
quencies frrr the training ~‘t and *:ach of the medical centers 
comprising the va!idation set. are 10.54 (p = 11.75) for the 
training set and 14.55 (p = 0.45). 23.68 fp = 0.1) and Lt.2 (p = 
0.X5) for each of the individual validatim sets (dettrees of 
lrcedtrm IS). The observed and estimated rtsk for cachof four 
ask categoric\ among the trsining set PIG as folittws: 3% versus 
2”;. l7’$ versus 14G. 23Y versus !h’T and 4fG vcnnts 54%. 
‘k observed and L ‘, imated risk for each risk category among 
the valtdation set are 4% versus 3%. 9Cf’ versus 12%. 1.5% 
vcr’+u\ ,)8? and 2b? vu “ius 424, 
The utility of stratification according to the models’ risk 
estimates is illurtraled in Figt:rc 4. When the clinical model 
was applied to all l,oI11 patients, the observed event rates were 
3%, 8% and 18C for patients classified as low (O-5%,), 
moderate (5-159) and high risk (>15%), respectively, (p < 
O.fKiOl). The addition of dipyridamole-thallium data re- 
classified HO% of !he moderate risk patients into low (3%) 
and high (19% ) risk categories (p c O.UOUl). However. 
dipyridamole-thallium testing provided no further risk dis- 
crimination amon: the patients defiqcd as either low (p *e 
t1.0111) or high (p = 0. I I) risk according to the clinical model, 
Risk eathate tab’ec. Table 4 lists the estimuted risk (post- 
test probability) of a f&operative cardiac eveat computed 
from a range of complication rates (prior probability) and the 
patient’s clinical risk score. These estimates were calculated 
using logistic regression-derived likelihood ratios (32-37). Ta- 
ble 5 provides risk estimates obtained from the dipyridamolc- 
thallium risk Kore. The prior probability for this model is 
defined as the posttest probability of the clinical model. The 
procedure required for estimating a patient-specific risk esti- 
mate from these tables is detailed in the Appendix. 
Discussion 
The present analysis expands on our earlier model (24) for 
predicting cardiac events by making use of a larger, more 
diverse population of vascular surgery c,ledidatcbs and limiting 
outcome dclinitioa to thr. ” hard” end points of myocardial 
Figure I. Receiver -upera~ing chrractcnrtic EUI)L* tar clinical and 
qucntidl Bayc\tau (IX., clmkal and dipyrid3mr,le-rh~llium) mud& 
dcrnul frclm thcb crsining ~‘1. Cinle~ = clinrcal m&l only, arrd 74 2 
3’;: wnam; - qu&ial Bay&n (clinical plus dipyridamole thalli- 
um), arca XI ? 37;. 
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I-spedfklly 
Vlparr 2, Rrcuivcr. cyrruting chturtrruuc TUYW fur vcquential 
bycnian mod& derived from the ttuinmg nd end ench of the three 
valid&n sets. Ctreles 1 training set (n = 567). arw HI f .W: 
= University of Vermont (n = 175), area 74 t UI: 
dZZt* = Deaconess ticxipital (n - 167). a:ca 72 + 71; inverse 
uiangka =: Yale (n .= 172). ares 76 ? SQ. 
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Ftgun 3. C;tlihrstion rcmltx from t&h the trrinin~ set (se&f rtnk 
n 17 567) end comhine4f v~li&ti~nr WI (aqrm etfetss. n _. $14) ( z SE of 
utwrvrd me). l?x o(RLCIVEJ and I rrimutcd rihk fur tuch of four id 
ca~rgoc~s ;~mtreg the training WI are as folks: 3% vrrsus 3%. 17% 
vcrw3 14S;. 23% wxsus 26% and 4tt% versus 54%. The c&md and 
csumstcd risk for cacb risk tategop among the vrtidmtton set are 4% 
wrsw 3%, 0% “er3us l2&, !J% vcws 28% und 26% versus 42%. 
infarction or cardiac death, Furthcrmorc. WC used an improved 
method of risk estimation that combines elements of Bayes 
theorem and logistic regression, yet requires no calculation 
beyond addition and subtraction of the risk estimate from 
Tables 4 and 5. A clear advantage to this method is that it 
permits consideration of the procedure-specific institutional 
complication rate in the estimation of risk. Another advantage 
to the use of logistic regression to calculate likelihood ratios is 
[ha: it ic nnt necessary to assume independe ncc between those 
variables included in each mode) (31). The logistic regression 
method used here has been successfully applied elsewhere 
(32-37) and is one of several related methods of deriving 
likelihood ratios using logistic regrzsion (40-43). Logistic 
models have also been applictl previously in a sequential 
Bayesian manner (44-46) to estimate cardiac risk in general 
populations. 
Dipyridamole-thallium testing provided further rehned risk 
strat;lication only among the patients classified as moderate 
risk (according to the clinical n~odcl): >&I% of these patients 
were reclassified as low or h&r risk. Thus, risk stratification 
according to the clinicat mod+ could reduce the need for 
further testing and may preverrt$he possible consequenccsof a 
false posithe result (unnmkry coronary angiography). 
Given the relatively high cost oti the thallium test, considerable 
savings are possible if its IW isi limited IU patients deemed to 
be at moderate risk according {o the dinical profile. 
In contrast to our earlier studies (19,2,4), we noted diffcr- 
ences in the type of variables and the values of the coefiients 
found IO be independently predictive of cardiac risk. This is 
probably a result of the larger size of our cohort and the 
selection of the “hard” end points of ronfatal myocardial 
infArction or cardiac death versus the softer end points of 
cardiac ischrmic events (including unstable angina) used in 
c.ne of the earlier studies (24). The prognostic accuracy of the 
models, as expressed t”/ the ROC areas, is similar to values 
published elsewhere for patients un&rgoing noncardiac sur- 
gery: f&sky et al. (1 I) reported a ROC area of HI ?. 4% for 
a multifactorial risk index, which is identical IO the value of 
81 i: 3% obtained for our Dequrntial Lyesian models. Also, as 
shown in Figure 4. risk stratification bs.sed on the clinical 
model alone could obviate the nerd for dipyridamole-thallium 
testing in nearly half the patients in this study. These pa- 
tients could not be further stratified ard therefore did not 
benefit from added te,,ting in the operative setting. 
valldatlosl asseMmeo ta. The validation assessments indi- 
cate some loss of prognostic~accuracy when the combined 
(clinical plus thallium) model v;as applied IO the validation set 
and some loss of reliability lo, tween observed and estimated 
events. For example. as shown in Figure 4, the model lcttds to 
overestimitc risk when app)ir:d to the challenge set, partic& 
larly ut IL: higher risk levels i>20%). However, the goodnem 
of tic p values indicate tha’ overall the estimated risk does 
correspond lo the observe 1 rates for each of the vahition 
sets. Although ROC arez’are less for the validation set then 
the training .w!, there va).des indicate that good discrimination 
remains (Le., all areas .xcerd 50%) and rre superior to the 
external wlidation reults reported elsewhere for a similar 
model (13). Such “st rinkage” may result from observed dif- 
ferences in the disttbution of risk facton behveen the event 
and nonevent grc.q.rs of patients between the training and 
validation sets (rahle I). However, it is reasonable to assume 
general compar,rbility between training and validation sets for 
the following canons: I) all centers included in the study are 
relatively lar;e urbsn [caching hospitals located in the north- 
t astern Un:led States; 2) both the training and validation sets 
included ~uccessirc vascular $urgety candidates relend to 
the resp.ictive institution’s cardiac nuclear laboratory for 
dipyridr~mole-thallium testing before major elective vascular 
surgeq ; 3) -6% of the training group and 6% of the validation 
set pa .ients were excluded because vascular surgery was post- 
Jlpyridarnttle-thalllllm le&tg and prompt vascular surgery 
al major univcroily mcdtcal ccnlcrs. Bccausc this is an 
nbscnational \~utly. the inJication for thallium was haaed on 
the clinician’s discrsticm, and as such. the patients in this 
study arc at 4ghtly higher risk than all vascular surgery 
candidatch. Thus, our model may therefore not be general- 
irahle IO all vascular surgery candidates. Further. because 
the model is based on patients who have already been 
selected for vascular surgery. it cannot be used to decide 
who Jhould undergo operation, that is, the model may be 
used to predict outcome among those patients who do 
undergo operation. 
One major source of bias in this .,rudy is tliat preoperz”ve 
dip~ridamolc-.tt~llium rcsulls were made available lo phy& 
cia4lc &ng for all patients and tcndcd to influence operative 
maniIgcmc;ll. I or c%amplc. tbcw patients with posi!i*e 
d&darn& -thallium images were likely to be more care:ully 
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monitored during operation and subjected to longer postoper- 
ativ, intensive cafe stays. 
Another potential biu may occur if risk factor assessment, 
Pippin, MD. Edward 1. Kmimki. MD. David Campbell. MD, Richard W. Nes&. 
MD. Thvnus Hill. MD. 
- 
obtained retrospectively from chart review, differs from risk 
factor determination by clinicians when the model is being Appendix 
applied. We recommend that evq effort be maue both to 
rcvicw the patient’s history and to consult the patient’s past Example of Risk Estimation hceduedure for 
medical record for confirmation of risk factor status. Individual Patients 
Cliokd implkations. The zugeested risk stratification 
scheme shown in Figure 4 demonstrates that a spectrum of 
clinical markers only, weighted according to prognostic impact, 
may significantly alter the prior probability of a pKtoperative 
cardiac event in a substantial number of patients rcferrcd for 
The c!mician should first obtain an cstimale of the iMilitutionat 
periopc.ative rate of nonfatal myoc&al infarction or cardiac death 
for the rcquirecl vrrrulvr rurgcty proc~~Jurc, such as the valws listed in 
Table 2. This ehtimatc is computed from the nunrber of eventsdivided 
by the total numhr of patients. For our exampk we will USE the 
dipyridamole-thallium testing, thus obviating the need for the 
more expensive cardiac screening. Also, the petijrmance of 
the clinical model indicates that it could be used by itself to 
estimate or stratify cardiac risk in patients not considered for 
further testing because of the urgency of the vascular proce- 
dure. However, it is also apparent from the thallium model 
that dipyridamole-thallium scanning reliably reclassifies a ma- 
jority of intermediate risk patients into low or high risk 
categories. 
The prediction models d-i in this report retain much of 
their prognostic accuracy when applied to the validation Sets and 
can also reliably estimate risk in this group. The models arc thus 
generaltile to vascular surgery caudidirtes who prcscnt for 
clecl~e operdtion at major university rncdical CeMers. 
p&operative cardiac complication rate for MXGC procedures, whii is 
6%. 
Second. the patient’s II&CA record should be cunsulted to obtain 
mformrCon on all clinical variables Ii& at the bottom of Table 4. 
With this list, the patient’s clinbl risk scorn is obtained by suntt~~ing 
lhe weights corresponding to ewh of 1he paliwl's clinical risk factor% 
For csample, if the patient wcrc a 6%yearutd candidale for aortic 
surgery with a hislory of dirbefcs and angina. the rbk score b 
Cliniul ww = 0.X (Drahctes) + Il.8 L4ngina) = 1.6. 
From Table 4, rhe estimaled risk of a perioperative cardiac event 
that corr‘sponds IO an institutional complicaGon rate of 6% and that 
falls within the clinical risk score range > I.5 to 2.0 is - 13%. Thus. the 
“average” risk of a complication (6%) IS rxsrd VI .- 13% for ati 
individudl patient who eahibh, the k,icn clin .: I isk factors 
Further risk discrimination basedon dlpriti* o&thallium resulta 
may be d&red it 1hc )laticnt wa$ rubseque~.1ly tes1ed and diiplaycd the 
L&nving results: positive ischcmic clectrocardiogr,rphic changes and a 
--- 
We ackmnulrdge ihc contributiuns of the follting 1~1 the developmenl of the 
validation data MS: From Yale tlnivcrrity, Stanley Rosenbaum, MD. Aan H. 
Nclwn, RN. Diwaker Jain, MD, Frans J. ‘DI. Wackers. MD, Barry L. Caret MD; 
frum Deaconess Hospital. Steven E. Lane. MD. Stanley M. Lewis. MD, John 1. 
retenihle myocardial defect. The weights from thL d~oyridamotc- 
thallium model shown at the bottom of ‘Table 5 corresponi:ag to these 
p :dictors are I ,2 and 1.3, respectively, L*r a total score of L.Z. 
‘Mlium score = I.? Ilschemic ST) + I 3 (Kc\cnihle defecll = 2.5. 
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